Drug Profile
NZV 930
Alternative Names: NZV-930; SRF-373Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Surface Oncology
- Developer Novartis; Surface Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Sep 2023 Surface Oncology has been acquired by Coherus BioSciences
- 31 Aug 2023 NZV 930 is still in phase I development in Solid tumours in USA, Canada, Hong Kong, Italy, Japan, Singapore, Spain and Taiwan (NCT04237649)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Canada (Parenteral)